Pioneering the Future of Cancer Care – Leading Oncology Startups at Onco:Innovate 2025 in Vienna

In the ever-evolving field of oncology, innovation is transforming how cancer is diagnosed, treated, and managed. The Onco:Innovate team has researched and compiled a list of nearly 100 cutting-edge oncology startups across Europe. These health innovators are introducing solutions that not only improve cancer detection and treatment but also provide essential post-treatment support for patients.

A select group of these innovators will present their groundbreaking solutions at the Onco:Innovate conference in Vienna on May 14th, 2025. The conference will showcase the latest advancements in cancer care, including AI-driven diagnostics, personalized therapies, and digital health tools that enhance patient outcomes.

Meet the Onco:Innovate Vienna 2025 startups

Digistain (UK/US) – Revolutionizing Cancer Recurrence Risk Assessment

Digistain is a UK-based medtech company transforming breast cancer diagnostics through its AI-powered optical scanning technology. The Digistain test utilizes infrared spectrometry to analyze tumor biopsies, capturing over 10,000 data points to generate a unique spectral signature. This data is processed using artificial intelligence to produce the Digistain Prognostic Score, a clear, single-digit risk score that predicts the likelihood of cancer recurrence within the next 10 years for patients treated with endocrine therapy alone. Unlike traditional genomic tests, Digistain’s approach is faster, more affordable, and seamlessly integrates into existing clinical workflows, enabling clinicians to make informed decisions about adjuvant chemotherapy and personalize patient care. This approach not only enhances diagnostic precision but also aids in determining the aggressiveness of the cancer, facilitating personalized treatment plans.​ Digistain is an Imperial College spinoff and a Y Combinator alumni. https://digistain.co.uk/  

Nutek MedTech (ISR/AT) – Advancing Precision Medicine

Nutek Medical is an innovative medtech company specializing in real-time cancer detection during surgery. Their flagship device, the Rainbow Probe, utilizes a miniaturized hyperspectral imaging system combined with AI-driven cloud algorithms to identify residual cancerous tissue directly on the patient’s body. This technology enables surgeons to verify the cavity surface’s cleanliness during procedures, potentially reducing the need for repeat surgeries and associated healthcare costs. Developed in collaboration with the Medical University of Graz, Austria, and supported by a grant from the Austrian Research Promotion Agency (FFG), the Rainbow Probe has undergone successful ex-vivo animal and human breast cancer pre-clinical testing.​ https://nutekmedtech.com/ 

Carebot (CZ) – AI-driven precision for earlier cancer detection 

Carebot is an AI-driven medical imaging platform designed to support oncologists in the early detection of cancer through advanced radiological analysis. Its AI-powered tools, such as AI CXR for chest X-rays and AI MMG for mammography, assist healthcare professionals by identifying subtle lesions and abnormalities with high sensitivity—up to 99% for chest X-rays. These tools integrate seamlessly into existing hospital PACS systems, enhancing workflow efficiency without disrupting physician routines. By enabling earlier and more accurate cancer detection, Carebot aims to improve patient outcomes and optimize healthcare resource utilization. https://www.carebot.com/en/carebot 

Docviser (RO) – Streamlining Oncology Treatment Planning

Docviser is an advanced oncology platform designed to streamline cancer treatment workflows through AI-driven tools and real-time collaboration. It offers features such as automated treatment protocol selection with precise dosage calculations, a patient scheduling system, and seamless communication between doctors, pharmacists, and nurses. The platform includes a virtual tumor board for multidisciplinary case discussions and an AI assistant capable of interpreting various medical documents and images. Certified with ISO 13485 and ISO 27001, Docviser ensures compliance with medical device and information security standards. With over 200 users across more than 40 hospitals in Romania, Docviser is transforming oncology care by enhancing efficiency and decision-making capabilities. https://docviser.io/ 

BiomeDX (AT) – Revolutionizing Cancer Immunotherapy with Microbiome Insights

Biome Diagnostics (BiomeDx) is an Austrian MedTech company pioneering precision oncology through microbiome-based diagnostics. Their flagship product, BiomeOne®, is the world’s first stool-based test that predicts patient responses to cancer immunotherapies, such as checkpoint inhibitors (e.g., anti-PD-1, anti-PD-L1, CTLA-4). By analyzing the gut microbiome, BiomeOne® identifies responders and non-responders to immunotherapy with over 80% accuracy, surpassing traditional PD-L1 expression testing. The test also assesses the likelihood of immune-related adverse events (irAEs), providing clinicians with actionable insights to personalize treatment plans. Certified as a CE-IVD medical device, BiomeOne® is currently available for melanoma, non-small cell lung cancer, and renal cell carcinoma patients, with results delivered within two weeks. BiomeDx’s innovative approach combines advanced DNA sequencing, machine learning algorithms, and a proprietary knowledge database, positioning the company at the forefront of microbiome-driven cancer care.​ https://www.biome-dx.com/ 

Womeno (BG) – Supporting Menopause After Cancer Care

Womeno is a digital health platform designed to support women experiencing menopause, including those who enter it prematurely due to cancer treatments like chemotherapy or surgery. By offering expert-led resources, personalized symptom assessments, and access to specialized care providers, Womeno helps women manage the physical and emotional effects of treatment-induced menopause, empowering them through recovery and beyond. https://womeno.me/ 

Verdi Solutions (AT) – Personalized Cancer Vaccines Powered by Genomic Precision

VERDI Solutions, based in Vienna, Austria, is a biotechnology startup dedicated to advancing personalized cancer immunotherapy. They specialize in designing tumor-targeted peptide vaccines tailored to each patient’s unique genetic profile. By analyzing tumor transcriptomics and HLA genotypes, VERDI’s platform identifies specific tumor antigens and models immune responses to select the most effective vaccine peptides. This approach aims to enhance the immune system’s ability to recognize and eliminate cancer cells, offering a promising avenue for individualized cancer treatment. Their services include tumor analysis, immune topology assessment, and vaccine design, all grounded in cutting-edge bioinformatics and immunology. VERDI Solutions is committed to revolutionizing cancer care through precision medicine, providing hope for more effective and personalized therapeutic options. https://www.verdisolution.com/ 

A Unified Vision for the Future of Oncology

The Onco:Innovate startups exemplify a collective commitment to advancing cancer care through innovation. From enhancing diagnostic accuracy and personalizing treatment plans to develop immunotherapies, these companies are united in their mission to improve patient outcomes and redefine the oncology landscape.​

As they continue to push the boundaries of what’s possible, the Onco:Innovate Innovators are not just shaping the future of cancer care—they are leading it.

Stay tuned for more Onco innovators at our upcoming demo days and conferences. 

Are you an innovator in the oncology sector yourself or do you want to get in touch with other innovators? Contact us at info@onco-innovate.org and join our network.